| 2022 | Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden | CLINICAL CHEMISTRY |
| 2022 | Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A | ESMO OPEN |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy
| CANCERS |
| 2022 | Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study | CLINICAL CANCER RESEARCH |
| 2022 | Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study
| EUROPEAN JOURNAL OF CANCER |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2022 | Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
| NEURO-ONCOLOGY |
| 2022 | Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
| CANCERS |
| 2022 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2022 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2022 | Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
| ESMO OPEN |
| 2021 | The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
| NATURE |
| 2021 | Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study | LANCET ONCOLOGY |
| 2021 | Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors | CLINICAL CANCER RESEARCH |
| 2021 | Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer | CELLULAR ONCOLOGY |
| 2021 | Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer
| CANCER MEDICINE |
| 2021 | Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
| GASTRIC CANCER |
| 2021 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses | HEPATOLOGY |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
| ANNALS OF ONCOLOGY |
| 2021 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia | TARGETED ONCOLOGY |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2021 | Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population
| GUT |
| 2021 | Detection of asymptomatic recurrence improves survival of gastric cancer patients
| CANCER MEDICINE |
| 2021 | Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
| CLINICAL CANCER RESEARCH |
| 2021 | MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
| FUTURE ONCOLOGY |
| 2021 | Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea
| CANCER RESEARCH AND TREATMENT |
| 2021 | Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial | CLINICAL CANCER RESEARCH |
| 2021 | First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
| FUTURE ONCOLOGY |
| 2021 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma | JOURNAL OF HEPATOLOGY |
| 2021 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis | EUROPEAN JOURNAL OF CANCER |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 2020 | Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
| Genomics & Informatics |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2020 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies | INTERNATIONAL JOURNAL OF CANCER |
| 2020 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study | LANCET ONCOLOGY |
| 2020 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial | JAMA ONCOLOGY |
| 2020 | Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
| FRONTIERS IN ONCOLOGY |
| 2020 | S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial | LANCET ONCOLOGY |
| 2020 | Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
| MOLECULAR THERAPY-ONCOLYTICS |
| 2020 | Waun Ki Hong, MD, D.M.Sc (Hon) (1942-2019): A Mentor Who Left Behind a Legacy for Generations to Come
| YONSEI MEDICAL JOURNAL |
| 2020 | Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
| CLINICAL CANCER RESEARCH |
| 2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
| GASTRIC CANCER |
| 2020 | Glutathione 주사에 의해 유발된 치명적인 천식발작 1예
| ALLERGY ASTHMA & RESPIRATORY DISEASE |
| 2020 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies | JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
| CLINICAL CANCER RESEARCH |
http://orcid.org/0000-0002-0920-9471
(7404006815)
